MRT-2359

MRT-2359 is an orally effective GSPT1 degrader that can inhibit the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells, with preferential activity against MYC-driven cell lines.

低至 ￥ 6910 /100mg

Orforglipron

Orforglipron is an orally active GLP-1 receptor agonist that promotes insulin secretion and suppresses appetite, widely used in research on diabetes and obesity-related metabolic diseases, with detailed information available in patent WO2018056453A1.

低至 ￥ 1764 /25mg

KT-474

KT-474 is a PROTAC IRAK4 degrader that demonstrates significant antitumor effects by mediating anticancer signals through IRAK4 targeted degradation.

低至 ￥ 3131 /25mg

Sotorasib/索托拉西布

Sotorasib is a KRAS G12C inhibitor with an IC50 value of 5.3 nM for KRAS G12C. Sotorasib has antitumor effects and can be used in research on KRAS mutation-associated cancers.

低至 ￥ 7585 /1g

MRTX1133

MRTX1133 is a highly selective KRAS G12D inhibitor that effectively suppresses its signaling pathways.

低至 ￥ 1925 /10mg

Emavusertib

Emavusertib (CA-4948) is an IRAK4/FLT3 inhibitor with oral and antitumor activities. The IC50 of Emavusertib to IRAK4 is 57 nM.

低至 ￥ 580 /10mg

Zabedosertib

Zabedosertib is a selective IRAK4 inhibitor with oral activity that can regulate immune responses.

低至 ￥ 328 /1mg

Zimlovisertib

Zimlovisertib (PF-06650833) is an effective, selective, and orally bioavailable inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) with an IC50 of 0.2 nM, and an IC50 of 2.4 nM in PBMC assays. Zimlovisertib has potential for research in rheumatoid arthritis, lupus, and lymphoma.

低至 ￥ 5166 /100mg

Danuglipron

PF-06882961 is a GLP-1R agonist. It works as a candidate drug for treatment for Type 2 Diabetes Mellitus in Phase 2 study.

低至 ￥ 1197 /10mg

Eragidomide

Eragidomide is a selective Cereblon E3 ligase modulator that selectively targets GSPT1 for ubiquitination and proteasomal degradation through CRL4^CRBN, making it significant for cancer research.

低至 ￥ 693 /10mg